Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer

Ramesk K Ramanathan, Jeffery W. Clark, Nancy E. Kemeny, Heinz Josef Lenz, Kim O. Gococo, Daniel G. Haller, Edith P. Mitchell, Carl G. Kardinal

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Purpose: Two consecutive compassionate use studies of oxaliplatin were conducted in the United States and Canada in more than 5,000 patients with locally advanced or metastatic colorectal carcinoma who had experienced treatment failure after at least one prior chemotherapy regimen. Patients and Methods: The main focus was safety. Patients were assigned to treatment with either single-agent oxaliplatin or oxaliplatin in combination with fluorouracil (FU) and with or without leucovorin (LV) in various regimens. Response data collection was not a trial objective, but time to treatment failure (TTF) was recorded in the first cohort (1,370 patients). Results: All treatment regimens were well tolerated, with an overall incidence of grade 3 or 4 hematologic toxicity of 23.2%, grade 3 or 4 treatment-related gastrointestinal toxicity of 26.4% (including diarrhea, vomiting, and mucositis), and grade 3 neurosensory toxicity 3.9%. Similar results were reported in the second cohort (3,806 patients), in which the eligibility criteria were much less restrictive. In the first cohort (in which 83% received prior irinotecan), median TTF was 14 weeks, and was similar for the five regimens combining oxaliplatin and FU with or without LV, but significantly shorter for the single-agent oxaliplatin arm. The overall dose-intensity of oxaliplatin was maintained at 85.5% (range, 80.6% to 94.3%) of that prescribed by protocol (average 36.7 mg/m2/wk). Conclusion: These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer.

Original languageEnglish (US)
Pages (from-to)2904-2911
Number of pages8
JournalJournal of Clinical Oncology
Volume21
Issue number15
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

oxaliplatin
Proxy
Fluorouracil
Colorectal Neoplasms
Safety
Treatment Failure
irinotecan
Leucovorin
Compassionate Use Trials
Salvage Therapy
Mucositis
Canada
Vomiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. / Ramanathan, Ramesk K; Clark, Jeffery W.; Kemeny, Nancy E.; Lenz, Heinz Josef; Gococo, Kim O.; Haller, Daniel G.; Mitchell, Edith P.; Kardinal, Carl G.

In: Journal of Clinical Oncology, Vol. 21, No. 15, 01.08.2003, p. 2904-2911.

Research output: Contribution to journalArticle

Ramanathan, Ramesk K ; Clark, Jeffery W. ; Kemeny, Nancy E. ; Lenz, Heinz Josef ; Gococo, Kim O. ; Haller, Daniel G. ; Mitchell, Edith P. ; Kardinal, Carl G. / Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 15. pp. 2904-2911.
@article{5a1445ae2182477fa718cb1c4373e064,
title = "Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer",
abstract = "Purpose: Two consecutive compassionate use studies of oxaliplatin were conducted in the United States and Canada in more than 5,000 patients with locally advanced or metastatic colorectal carcinoma who had experienced treatment failure after at least one prior chemotherapy regimen. Patients and Methods: The main focus was safety. Patients were assigned to treatment with either single-agent oxaliplatin or oxaliplatin in combination with fluorouracil (FU) and with or without leucovorin (LV) in various regimens. Response data collection was not a trial objective, but time to treatment failure (TTF) was recorded in the first cohort (1,370 patients). Results: All treatment regimens were well tolerated, with an overall incidence of grade 3 or 4 hematologic toxicity of 23.2{\%}, grade 3 or 4 treatment-related gastrointestinal toxicity of 26.4{\%} (including diarrhea, vomiting, and mucositis), and grade 3 neurosensory toxicity 3.9{\%}. Similar results were reported in the second cohort (3,806 patients), in which the eligibility criteria were much less restrictive. In the first cohort (in which 83{\%} received prior irinotecan), median TTF was 14 weeks, and was similar for the five regimens combining oxaliplatin and FU with or without LV, but significantly shorter for the single-agent oxaliplatin arm. The overall dose-intensity of oxaliplatin was maintained at 85.5{\%} (range, 80.6{\%} to 94.3{\%}) of that prescribed by protocol (average 36.7 mg/m2/wk). Conclusion: These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer.",
author = "Ramanathan, {Ramesk K} and Clark, {Jeffery W.} and Kemeny, {Nancy E.} and Lenz, {Heinz Josef} and Gococo, {Kim O.} and Haller, {Daniel G.} and Mitchell, {Edith P.} and Kardinal, {Carl G.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1200/JCO.2003.11.045",
language = "English (US)",
volume = "21",
pages = "2904--2911",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "15",

}

TY - JOUR

T1 - Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer

AU - Ramanathan, Ramesk K

AU - Clark, Jeffery W.

AU - Kemeny, Nancy E.

AU - Lenz, Heinz Josef

AU - Gococo, Kim O.

AU - Haller, Daniel G.

AU - Mitchell, Edith P.

AU - Kardinal, Carl G.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Purpose: Two consecutive compassionate use studies of oxaliplatin were conducted in the United States and Canada in more than 5,000 patients with locally advanced or metastatic colorectal carcinoma who had experienced treatment failure after at least one prior chemotherapy regimen. Patients and Methods: The main focus was safety. Patients were assigned to treatment with either single-agent oxaliplatin or oxaliplatin in combination with fluorouracil (FU) and with or without leucovorin (LV) in various regimens. Response data collection was not a trial objective, but time to treatment failure (TTF) was recorded in the first cohort (1,370 patients). Results: All treatment regimens were well tolerated, with an overall incidence of grade 3 or 4 hematologic toxicity of 23.2%, grade 3 or 4 treatment-related gastrointestinal toxicity of 26.4% (including diarrhea, vomiting, and mucositis), and grade 3 neurosensory toxicity 3.9%. Similar results were reported in the second cohort (3,806 patients), in which the eligibility criteria were much less restrictive. In the first cohort (in which 83% received prior irinotecan), median TTF was 14 weeks, and was similar for the five regimens combining oxaliplatin and FU with or without LV, but significantly shorter for the single-agent oxaliplatin arm. The overall dose-intensity of oxaliplatin was maintained at 85.5% (range, 80.6% to 94.3%) of that prescribed by protocol (average 36.7 mg/m2/wk). Conclusion: These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer.

AB - Purpose: Two consecutive compassionate use studies of oxaliplatin were conducted in the United States and Canada in more than 5,000 patients with locally advanced or metastatic colorectal carcinoma who had experienced treatment failure after at least one prior chemotherapy regimen. Patients and Methods: The main focus was safety. Patients were assigned to treatment with either single-agent oxaliplatin or oxaliplatin in combination with fluorouracil (FU) and with or without leucovorin (LV) in various regimens. Response data collection was not a trial objective, but time to treatment failure (TTF) was recorded in the first cohort (1,370 patients). Results: All treatment regimens were well tolerated, with an overall incidence of grade 3 or 4 hematologic toxicity of 23.2%, grade 3 or 4 treatment-related gastrointestinal toxicity of 26.4% (including diarrhea, vomiting, and mucositis), and grade 3 neurosensory toxicity 3.9%. Similar results were reported in the second cohort (3,806 patients), in which the eligibility criteria were much less restrictive. In the first cohort (in which 83% received prior irinotecan), median TTF was 14 weeks, and was similar for the five regimens combining oxaliplatin and FU with or without LV, but significantly shorter for the single-agent oxaliplatin arm. The overall dose-intensity of oxaliplatin was maintained at 85.5% (range, 80.6% to 94.3%) of that prescribed by protocol (average 36.7 mg/m2/wk). Conclusion: These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=0042386685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042386685&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.11.045

DO - 10.1200/JCO.2003.11.045

M3 - Article

C2 - 12885808

AN - SCOPUS:0042386685

VL - 21

SP - 2904

EP - 2911

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -